Long-Acting Growth Hormone Releasing Hormone (GHRH) Analogue
Disclaimer: This product is for laboratory research purposes only. Not for human consumption.
Standardized handling, dosing, and storage guidelines for CJC-1295 With DAC in metabolic and hypertrophy research applications.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH). The addition of the DAC significantly extends its half-life by binding to serum albumin, allowing for sustained, physiological pulsatile release of growth hormone and IGF-1 over several days. This makes it a highly effective compound for research focused on long-term muscle hypertrophy, lipolysis, cellular repair, and improvements in deep sleep architecture without the need for frequent daily administrations.
The DAC binds to endogenous albumin, extending the half-life. Initial increases in basal GH and IGF-1 are established. Subjects often experience improvements in sleep quality and mild lethargy.
| Compound | Primary Mechanism | Key Benefit | Admin. |
|---|---|---|---|
| CJC-1295 w/ DAC | Long-acting GHRH | Sustained GH pulses & IGF-1 elevation | SubQ |
| CJC-1295 No DAC | Short-acting GHRH | Acute, short-lived GH spike | SubQ |
| Ipamorelin | GHRP (Secretagogue) | Synergistic GH release without cortisol spikes | SubQ |
| Tesamorelin | GHRH Analogue | Targeted visceral fat reduction | SubQ |
The Drug Affinity Complex (DAC) allows the peptide to bind to endogenous serum albumin, protecting it from rapid enzymatic degradation and extending its activity window.
The maleimidopropionyl group (DAC) binds covalently to serum albumin in the bloodstream, preventing rapid clearance by the kidneys.
Continuously binds to GHRH receptors on the anterior pituitary gland over a period of several days.
Promotes a physiological, pulsatile release of Growth Hormone, subsequently elevating systemic IGF-1 levels for tissue repair and growth.
Extended half-life of 5-8 days due to the Drug Affinity Complex (DAC).
High via subcutaneous injection, allowing for once or twice weekly dosing schedules.
Gradual renal and hepatic degradation as the albumin-peptide complex is metabolized.
Highly specific for GHRH receptors on somatotropes in the anterior pituitary.
CJC-1295 with DAC has been extensively studied for its ability to elevate basal GH and IGF-1 levels without disrupting natural pulsatile rhythms.
Explores how albumin binding extends the half-life of GHRH analogues for sustained research.
SYNERGYA deep dive into combining GHRH and GHRP compounds for maximum physiological impact.
RECOVERYReviews the efficacy of sustained GH elevation in promoting tissue regeneration and deep sleep.
Explore research-use products associated with this compound profile, including available formats, related blends, and supporting lab documentation where available.
Deeper research-focused questions about CJC-1295 With DAC, GHRH analogue research, Drug Affinity Complex technology, albumin binding, GH/IGF-1 axis models, storage, and batch documentation.
CJC-1295 With DAC is a synthetic growth hormone-releasing hormone analogue commonly discussed in GH/IGF-1 axis research. The “With DAC” version includes a Drug Affinity Complex modification designed to extend the compound’s research half-life through albumin-binding behavior. In research contexts, CJC-1295 With DAC is studied around sustained GHRH receptor activation, growth hormone secretion models, IGF-1 response, pituitary signaling, and long-acting peptide pharmacokinetic design. On this site, CJC-1295 With DAC is positioned strictly as a laboratory research reference compound.
DAC stands for Drug Affinity Complex. In CJC-1295 With DAC, this modification is commonly discussed as the feature that allows the peptide to bind to albumin and remain active in research models for a longer period than shorter-acting GHRH analogues. For SEO and education, the DAC distinction is important because CJC-1295 With DAC and CJC-1295 No DAC are often searched together but represent different pharmacokinetic research profiles.
CJC-1295 With DAC is commonly described as a long-acting analogue of growth hormone-releasing hormone, also called GHRH or GRF. GHRH is the endogenous signaling hormone that interacts with GHRH receptors in the pituitary axis. CJC-1295 With DAC is studied as a modified GHRH analogue because it is designed to preserve GHRH receptor pathway activity while extending exposure time through the DAC modification.
The main difference is the DAC modification. CJC-1295 With DAC is generally discussed as the long-acting version because the Drug Affinity Complex supports albumin binding and extended exposure in research models. CJC-1295 No DAC, often associated with Mod GRF 1-29 terminology, is typically discussed as a shorter-acting GHRH analogue. For resource pages, this distinction matters because With DAC pages should emphasize sustained signaling and pharmacokinetic design, while No DAC pages should emphasize shorter-duration GHRH analogue research.
Albumin binding is important because albumin is a major circulating protein that can influence how long certain modified compounds remain available in biological research systems. The DAC modification in CJC-1295 With DAC is commonly discussed as a peptide-engineering strategy that extends exposure time by associating with albumin. This makes albumin binding one of the core science angles for a CJC-1295 With DAC resource page.
CJC-1295 With DAC is studied in GH and IGF-1 research because GHRH receptor signaling is connected to growth hormone secretion and downstream insulin-like growth factor 1 response. In laboratory and clinical research discussions, CJC-1295 is often examined for sustained GH and IGF-1 axis activity compared with shorter-acting GHRH analogues. A research-use page should describe this as endocrine-axis research rather than as a wellness, anti-aging, bodybuilding, or treatment claim.
CJC-1295 With DAC is commonly associated with research areas involving GHRH receptor signaling, growth hormone secretion models, IGF-1 response, pituitary-axis research, endocrine pulsatility, long-acting peptide pharmacokinetics, albumin-binding peptide design, and sustained hormone-axis pathway modeling. It is best positioned as a GHRH analogue research compound rather than a repair peptide, melanocortin compound, metabolic receptor agonist, or cosmetic peptide.
CJC-1295 With DAC research discussions may involve endpoints related to GH secretion, IGF-1 response, GHRH receptor activity, pituitary signaling, endocrine pulsatility, pharmacokinetic duration, albumin-associated exposure, and downstream hormone-axis markers. The exact endpoints depend on the research model, study design, analytical methods, and whether the focus is receptor activity, hormone secretion patterns, or long-acting peptide formulation design.
CJC-1295 With DAC, Ipamorelin, and Sermorelin are all commonly discussed in growth hormone axis research, but they are not identical compounds. Sermorelin is usually discussed as a GHRH analogue, CJC-1295 With DAC as a longer-acting GHRH analogue with albumin-binding pharmacokinetic design, and Ipamorelin as a growth hormone secretagogue commonly associated with ghrelin receptor research. These pages should be internally linked but kept separate because the mechanisms and SEO angles are different.
No. In common peptide terminology, Modified GRF 1-29 is usually associated with CJC-1295 No DAC rather than CJC-1295 With DAC. CJC-1295 With DAC includes the Drug Affinity Complex modification that gives it a longer-acting research profile, while Modified GRF 1-29 lacks that DAC extension. Because these names are often confused online, a CJC-1295 With DAC resource page should clearly explain the difference to improve both user understanding and SEO clarity.
CJC-1295 With DAC should not be presented as an approved medication, prescription product, anti-aging treatment, bodybuilding compound, or self-administered therapy. Research-use material sold by Symbiotic Pharmaceuticals should not be confused with a regulated pharmaceutical product or clinical protocol. This page is written only for educational reference and laboratory research positioning.
Storage requirements can vary by product format, batch, and label instructions. For research handling, follow the product label and applicable laboratory storage standards. In general, research peptides should be protected from unnecessary heat, light, moisture, contamination, and repeated temperature changes because these conditions may affect long-term stability and handling quality.
Available certificates of analysis and batch documentation can be reviewed through the Lab Results / COA page. Documentation availability may vary by product and inventory lot. Where available, batch documentation may include product identification, purity-focused testing references, and supporting analytical documentation.
Yes. CJC-1295 With DAC products listed on Symbiotic Pharmaceuticals are intended for laboratory research and analytical reference use only. They are not intended for human consumption, animal consumption, diagnostic use, therapeutic use, hormone treatment, anti-aging use, bodybuilding use, injection use, or self-administration. Any discussion on this page is provided for educational and research-reference purposes only.
The information provided in this resource hub is for educational and informational purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease.
